Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation

Galderma, a global leader in aesthetics and dermatology, is celebrating the 25th anniversary of its pioneering biostimulator, Sculptra®. With a quarter-century of innovation and clinical success, Sculptra® continues to set the standard in regenerative biostimulation. Recent data and approvals further cement Galderma's leadership in this field, offering investors an attractive opportunity to capitalize on the company's stable profits and cash flows.

Sculptra®'s unique mechanism of action sets it apart from other biostimulators like Calcium Hydroxyapatite (CaHA-R). Galderma's research, presented at the American Society for Dermatologic Surgery (ASDS) 2024, revealed that Sculptra's Poly-L-Lactic Acid (PLLA-SCA) triggers regenerative morphogenesis in facial skin, while CaHA-R induces inflammation. This difference enables Sculptra® to stimulate collagen production and tissue regeneration, leading to longer-lasting results.


The expansion of Sculptra®'s applications over 25 years has contributed to its market dominance in regenerative biostimulation. Initially launched as a treatment for facial lipoatrophy, Sculptra®'s versatility has since expanded to address volume loss, wrinkles, and even hand rejuvenation. Galderma's symposium at the International Master Course on Aging Science (IMCAS) 2024, "The AART™ of Sculptra," will explore how its applications have expanded, enabling practitioners to identify the right patient profiles using a holistic facial assessment tool.


Galderma's recent approval of Sculptra® in China further strengthens its global leadership in aesthetics and regenerative medicine. With a population of over 1.4 billion, China represents the world's largest aesthetics market, with a CAGR of 14.2% expected until 2028. This approval allows Galderma to tap into this vast market, further cementing its leadership in regenerative biostimulation.

Investors seeking stable income and long-term growth should consider Galderma as an attractive option. The company's commitment to innovation and clinical research, as seen in their symposia and posters at IMCAS and ASDS, ensures practitioners stay informed about the latest advancements and best practices, further solidifying Sculptra®'s leadership in the field.

In conclusion, Galderma's Sculptra® continues to lead the way in regenerative biostimulation, with a quarter-century of success and a promising future. Investors looking for stable profits and cash flows should consider Galderma as a reliable income-generating investment, supported by strong institutional stability and a commitment to innovation.